Hebert A, Glaab D, Schreiber R. A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis. J of Skin [Internet]. 2019Mar.11 [cited 2024Jul.22];3(2):171. Available from: https://jofskin.org/index.php/skin/article/view/528